(S)-Magnoflorine is a quaternary benzylisoquinoline alkaloid (BIA) of the aporphine structural subgroup which has been isolated from various species of the family Menispermaceae, such as Pachygone ovata,[1] Sinomenium acutum,[2] and Cissampelos pareira.

[3] It was identified among the verified anti-inflammatory components in an extract of Sinomenii caulis[4] and has been proposed to have other potential physiological effects, such as sedative and anxiolytic,[2] reduction of erythrocyte hemolysis,[5] antifungal activity,[6] improvement of LPS-induced acute lung injury,[7] and protection against muscle atrophy.

[8] Furthermore, magnoflorine has been identified to be an inhibitor of NF-κB activation and to be an agonist at the β2 -adrenergic receptor.

[9] (S)-Magnoflorine is metabolically derived from (S)-reticuline, a pivotal intermediate in the biosynthesis of numerous BIA structural subgroups, through two enzymatic steps: first, (S)-corytuberine synthase/CYP80G2 to (S)-corytuberine, and secondly, (S)-corytuberine-N-methyltransferase to (S)-magnoflorine.

This article about an alkaloid is a stub.